ArticleEndocrine2026
Anaplastic thyroid cancer: Cases, incidence, prevalence and survival in Germany.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBecause anaplastic thyroid cancer (ATC) is a rare diagnosis, detailed epidemiological data are difficult to find in publicly accessible platforms. The aim of this study was to report current incidence and survival estimates for ATC in Germany and to analyse their trends over time.
methodsData from the population-based cancer registries in Germany were pooled. ATC was classified according to the International Classification of Diseases, 10th edition (ICD-10). Age-standardised incidence rates (per 100,000) for the years 2011 to 2022 were calculated. The relative survival was estimated using period analysis. Annual percentage changes (APC) in the incidence and survival trends over time were computed.
findingsThe number of new ATC cases diagnosed between 2011 and 2022 was 2127 (924 in men and 1203 in women). The current raw incidence is 0.19 in men and 0.22 in women. The age-standardised incidence in men changed slightly, but not significantly, during this period (APC − 2%, p = 0.126; recent rate 0.11) while it decreased in women (APC − 3%, p < 0.001; recent rate 0.10). The five-year relative survival ranged from 11% (2020–2022) to 15% (2017–2019) and decreased considerably with age. There were no differences in survival between men and women and no evidence for a change in survival over time.
conclusionAbout two persons per 1 million inhabitants are currently diagnosed with ATC per year. Over the past 12 years, there was a slight decrease in ATC incidence, especially in women, while survival remained largely unchanged during this period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.